Filtered By:
Specialty: Cardiology
Drug: Lipitor
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 690 results found since Jan 2013.
Cerebrovascular Disease and Statins
Front Cardiovasc Med. 2021 Dec 2;8:778740. doi: 10.3389/fcvm.2021.778740. eCollection 2021.ABSTRACTElevated low-density lipoprotein-cholesterol (LDL-C) is a causal factor for the development of atherosclerotic cardiovascular disease (ASCVD); accordingly, LDL-C lowering is associated with a decreased risk of progression of atherosclerotic plaques and development of complications. Currently, statins play a central role in any ASCVD management and prevention strategies, in relation to their lipid-lowering action and potentially to pleiotropic effects. After coronary artery disease, stroke is the most frequent cause of ASCVD m...
Source: Atherosclerosis - December 20, 2021 Category: Cardiology Authors: Luis M Beltr án Romero Antonio J Vallejo-Vaz Ovidio Mu ñiz Grijalvo Source Type: research
Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study
ConclusionsPatients undergoing a coronary revascularization procedure who received moderate-intensity statins plus ezetimibe showed similar rates of major adverse cardiovascular events as patients who received high-intensity statins.
Source: Cardiovascular Drugs and Therapy - September 17, 2021 Category: Cardiology Source Type: research
SPARCL: Atorvastatin Stroke Benefit Reinforced in New Analysis SPARCL: Atorvastatin Stroke Benefit Reinforced in New Analysis
A new analysis of the SPARCL trial has shown that the total number of vascular events prevented with atorvastatin was more than twice the number of first events prevented.Medscape Medical News
Source: Medscape Cardiology Headlines - March 23, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news
Effect of high-dose strong statin for preventing periprocedural ischemic complications of carotid artery stenting
This study assessed the safety and usefulness of pretreatment using a high-dose strong statin (HDSS) to reduce the periprocedural ischemic complications of CAS. We analyzed 117 carotid lesions treated by CAS that were evaluated with magnetic resonance imaging (MRI) within 48 h after the procedure. For 67 lesions, an HDSS (rosuvastatin 20 mg or atorvastatin 40 mg daily) were prescribed from at least 14 days before CAS to at least 14 days after procedure (HDSS group). Clinical and angiographic data, as well as in-hospital outcomes, of the HDSS group were retrospecti vely compared with 50 lesions with conventional treat...
Source: Heart and Vessels - January 9, 2020 Category: Cardiology Source Type: research
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
Publication date: Available online 9 August 2019Source: American Heart JournalAuthor(s): Kausik K. Ray, Stephen J. Nicholls, Henry Ginsberg, Jan O. Johansson, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Peter P. Toth, Norman Wong, Jeffrey L. Cummings, Michael Sweeney, Gregory G. SchwartzAbstractBackgroundAfter an acute coronary syndrome (ACS), patients with diabetes remain at high risk for additional cardiovascular events despite use of current therapies. Bromodomain and extra-terminal (BET) proteins are epigenetic modulators of inflammation, thrombogenesis, and lipoprotein metabolism implicated in atherothrombosis. The BET...
Source: American Heart Journal - August 9, 2019 Category: Cardiology Source Type: research
Impact of ADCY9 Genotype on Response to Anacetrapib.
CONCLUSIONS: The REVEAL trial is the single largest study to date evaluating the ADCY9 pharmacogenetic interaction. It provides no support for the hypothesis that ADCY9 genotype is materially relevant to the clinical effects of the CETP inhibitor anacetrapib. The ongoing dal-GenE study will provide direct evidence as to whether there is any specific pharmacogenetic interaction with dalcetrapib.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov Unique Identifier: NCT01252953; URL: http://www.isrctn.com Unique Identifier: ISRCTN48678192; URL: https://www.clinicaltrialsregister.eu Unique Identifier: 2010-0...
Source: Circulation - July 22, 2019 Category: Cardiology Authors: Hopewell JC, Ibrahim M, Hill M, Shaw PM, Braunwald E, Blaustein RO, Bowman L, Landray MJ, Sabatine MS, Collins R, HPS3/TIMI55 - REVEAL Collaborative Group Tags: Circulation Source Type: research
Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons
ConclusionsAmong PWH with statin indication(s), blacks and Hispanics were less likely than whites to have been prescribed a statin. These racial/ethnic disparities were less pronounced among uninfected persons. There were significant differences in type of statin used for PWH compared to uninfected matched controls. Future efforts addressing disparities in CVD prevention among PWH are warranted.
Source: American Heart Journal - January 25, 2019 Category: Cardiology Source Type: research
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis and network meta-analysis of randomized trials with 94,283 participants
ConclusionsAll statins showed statistically significant risk reduction of CVD and all-cause mortality in primary prevention populations while increasing the risk for some harm risks. However, the benefit-harm profile differed by statin type. A quantitative assessment of the benefit-harm balance is thus needed since meta-analyses alone are insufficient to inform whether statins provide net benefit.
Source: American Heart Journal - January 11, 2019 Category: Cardiology Source Type: research
Differences in Statin Utilization and Lipid-Lowering by Race, Ethnicity, and HIV Status in a Real-World Cohort of Persons with Human Immunodeficiency Virus and Uninfected Persons
ConclusionsAmong PWH with statin indication(s), Blacks and Hispanics were less likely than whites to have been prescribed a statin. These racial/ethnic disparities were less pronounced among uninfected persons. There were significant differences in type of statin utilized for PWH compared to uninfected matched controls. Future efforts addressing disparities in CVD prevention among PWH are warranted.
Source: American Heart Journal - December 21, 2018 Category: Cardiology Source Type: research
High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study
ConclusionsAmong clinically stable DES-treated patients on aspirin monotherapy, high-intensity statin treatment significantly reduced late adverse events compared with low-intensity statin treatment.Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01557075.ResumenIntroducción y objetivosLa vigente guía de práctica clínica para el tratamiento de la hipercolesterolemia recomienda mantener la terapia intensiva con estatinas de los pacientes tratados con implante de stent farmacoactivo (SFA). Sin embargo, el tratamiento intensivo con estatinas, una vez estabilizado el paciente, con fre...
Source: Revista Espanola de Cardiologia - July 10, 2018 Category: Cardiology Source Type: research
Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial.
Conclusions -The present post-hoc analysis from TNT shows that increased TRL-C levels associate an increased cardiovascular risk and provides evidence for the cardiovascular benefit of lipid-lowering with statins among CHD patients with high TRL-C. Clinical Trial Registration -URL: https://clinicaltrials.gov Unique Identifier: NCT00327691.
PMID: 29618599 [PubMed - as supplied by publisher]
Source: Circulation - April 4, 2018 Category: Cardiology Authors: Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK Tags: Circulation Source Type: research
Rationale and Design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial
Publication date: Available online 8 January 2018 Source:American Heart Journal Author(s): Otavio Berwanger, Pedro G.M. de Barros e Silva, Frederico Toledo Campo Dall Orto, Pedro Beraldo de Andrade, Igor Ribeiro de Castro Bienert, Carlos Eduardo Bosso, José Mangione, Carisi Anne Polanczyk, Amanda Sousa, Renato Kalil, Luciano de Moura Santos, Andrei C. Sposito, Rafael L. Rech, Antonio Carlos Sobral Sousa, Felipe Baldissera, Bruno Ramos Nascimento, Isabella de Andrade Jesuíno, Eliana Vieira Santucci, Lucas Petri Daminani, Ligia N Laranjeira, Juliana A Borges de Oliveira, Roberto R Giraldez, Alexandre Biasi Cavalcanti, Sab...
Source: American Heart Journal - January 9, 2018 Category: Cardiology Source Type: research
The short-term effect of atorvastatin plus ezetimibe therapy versus atorvastatin monotherapy on clinical outcome in acute coronary syndrome patients by gender.
CONCLUSIONS: The results of our study demonstrated that when added to statin therapy, EZE resulted in improved cardiovascular outcomes, and the response to atorvastatin and EZE combination was similar for both men and women.
PMID: 28553847 [PubMed - indexed for MEDLINE]
Source: Kardiologia Polska - December 6, 2017 Category: Cardiology Authors: Japaridze L, Sadunishvili M Tags: Kardiol Pol Source Type: research
